CSRXP STATEMENT ON PRESIDENT TRUMP’S MOST FAVORED NATION EXECUTIVE ORDER
Administration Rightly Diagnoses Big Pharma’s Egregious Pricing Practices as Root Cause of High Drug Prices in America, Can Help Lower Prices by Supporting Solutions to Boost Competition
For Immediate Release
May 13, 2025
Contact: Jon Conradi
[email protected]
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued the following statement on Tuesday on President Trump's signing of an executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.”
“CSRxP appreciates President Trump’s commitment to lowering prescription drug prices in America, and for rightly diagnosing the egregious prices set by Big Pharma as the root cause of the problem,” said CSRxP spokesman Jon Conradi. “CSRxP looks forward to reviewing the full details of the policy initiatives outlined by the recent executive order and encourages the Administration to build on its commitment to lowering drug prices for patients now, by lending its strong support to bipartisan, bicameral work on Capitol Hill to hold Big Pharma accountable for egregious abuse of the U.S. patent system that costs American patients and taxpayers billions of dollars each year.”
A recent national survey of U.S. voters, commissioned by CSRxP and conducted by Trump campaign pollster Fabrizio Ward, found Americans continue to be very concerned with high drug prices, hold drug companies responsible for high drug prices and support market-based solutions to lower prices by holding big drug companies accountable, including for gaming the U.S. patent system to block competition.
- Nine in ten voters expressed concern about the cost of prescription drugs in the U.S.
- 62 percent of voters view drug companies as the most responsible for high drug costs out of eight options.
- 82 percent of voters support patent reforms to prevent drug companies from abusing the system to prevent cheaper alternatives from entering the market.
“The electorate, including equal numbers of Trump and Harris Voters, holds intensely unfavorable views of drug companies,” pollsters Tony Fabrizio and Bob Ward wrote in a memo on their findings. “By wide margins, voters are very concerned about the cost of Rx drugs, hold drug companies responsible and clearly identify drug company profits as the driver of high drug costs. Members of Congress, including Republicans, would ignore this extraordinary voter sentiment at their peril. In fact, Republicans on the Hill should be looking to the White House for guidance on this issue as Trump Voters trust the President over Republicans in Congress by a three-to-one margin to address the issue of prescription drug prices.”
Learn more on Big Pharma’s patent abuse that blocks competition and keeps drug prices high HERE.
Read more on bipartisan, market-based solutions to hold Big Pharma accountable HERE.
###
